retatrutide and ipamorelin Training & Recovery Optimization Performance Protocol Completed 💉 Peptide protocol: * * CJC-1295 / * GHK-Cu peptide 🏋️ Training: * 1 hour gym session completed CJC 1295, ipamorelin and retatrutide:

235.00 For research use only Not for human or animal use Retatrutide 60mg Pen is a triple receptor agonist developed by Eli Lilly and studied for its effects on metabolism, appetite signalling, and body weight regulation

In Phase 2 trials, participants shed as much as 24% of their body weight with 7.2% to 17.5% average losses between dose groups at 24 weeks

12-14 In phase III clinical studies in which exenatide was administered concomitantly with metformin, an SU, or metformin plus an SU, 48% of the 483 patients receiving exenatide 10 mcg twice daily reported nausea compared to 18% of the 483 patients receiving placebo

Employers that cover GLP-1 medications for obesity are improving the health of their members